Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 830 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 830 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $45.00, for a total transaction of $37,350.00. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $564,570. This represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded down $1.44 during trading hours on Wednesday, reaching $43.52. 523,927 shares of the company traded hands, compared to its average volume of 698,512. Kiniksa Pharmaceuticals International, plc has a 1-year low of $18.12 and a 1-year high of $45.50. The stock has a market cap of $3.30 billion, a P/E ratio of 96.71 and a beta of 0.06. The stock’s fifty day moving average is $41.78 and its 200 day moving average is $38.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the prior year, the business posted ($0.18) EPS. Kiniksa Pharmaceuticals International’s revenue was up 61.2% compared to the same quarter last year. On average, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds have recently modified their holdings of KNSA. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. USA Financial Formulas bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. Quantbot Technologies LP acquired a new position in Kiniksa Pharmaceuticals International in the second quarter worth $43,000. Finally, Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $44,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several analyst reports. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Finally, Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.